



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/533,272	04/28/2005	Ian James Collins	T1599YP	7510
210	7590	10/19/2007	EXAMINER	
MERCK AND CO., INC			CHUNG, SUSANNAH LEE	
P O-BOX 2000			ART UNIT	PAPER NUMBER
RAHWAY, NJ 07065-0907			1626	
			MAIL DATE	DELIVERY MODE
			10/19/2007	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	Application No. 10/533,272	Applicant(s) COLLINS ET AL.	
	Examiner Susannah Chung	Art Unit 1626	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 28 April 2005.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 1-7, 10 and 11 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-7 and 10 is/are rejected.
- 7) ☒ Claim(s) 11 is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date <u>4/28/2005</u> . | 6) <input type="checkbox"/> Other: _____  |

### DETAILED ACTION

Claims 1-7 and 10-11 are pending in the instant application. Claims 8 and 9 are canceled by preliminary amendment.

#### *Priority*

This application is a 371 of PCT/GB03/04728, filed 10/31/2003.

Acknowledgment is made of applicant's claim for foreign priority under 35 U.S.C. 119(a)-(d) by application no. 0225475.3, filed in the United Kingdom Patent Office on 11/1/2002, which papers have been placed of record in the file. The application names an inventor or inventors named in the prior application.

#### *Information Disclosure Statement*

The information disclosure statement (IDS), filed on 4/28/05 has been considered. Please refer to Applicant's copy of the 1449 submitted herewith.

#### *Obviousness Double Patenting*

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute), so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground


Art Unit: 1626

provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-7 and 10 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over Claims 1-16 of U.S. Patent Num. 7,041,689, Claims 1-6 of U.S. Patent Num. 7,138,400, and Claims 1-10 of U.S. Patent Num. 7,282,513.


The instant claims disclose a compound of formula (I),



for use in the treatment of Alzheimer's disease.


Determination of the scope and content of the prior art (MPEP § 2141.01)

Claims 1-16 of U.S. Patent Num. 7,041,689 teach compounds of formula (I),




Art Unit: 1626

Claims 1-6 of U.S. Patent Num. 7,138,400 teach compounds of formula (I(D)),



Claims 1-10 of U.S. Patent Num. 7,282,513 teach compounds of formula (X(a)),



Ascertainment of the difference between the prior art and the claims (MPEP § 2141.02)

The difference between the prior patents and the instant application is the scope of the invention disclosed. For example, U.S. Patent Num. 7,041,689 teaches a compound wherein R<sub>2</sub> is a fixed -CH<sub>2</sub>-CF<sub>3</sub> group, while in the instant application R<sub>2</sub> is a hydrocarbon group optionally substituted with up to 3 halogens.

Finding of prima facie obviousness – rationale and motivation (MPEP § 2142-2413)

Although the conflicting claims are not identical, they are not patentably distinct from each other because the same compounds, compositions, and use are taught in the prior patents

Art Unit: 1626

and the instant application. Utilizing the methods of production found in the prior patents the instantly claimed compounds can be synthesized. One skilled in the art would find the variations in scope to be mere optimization of a known compound and expect similar properties and results. The motivation to optimize the compounds of the prior patents is that they will have similar pharmacological use.

MPEP 804 states: The doctrine of double patenting seeks to prevent the unjustified extension of patent exclusivity beyond the term of a patent. The public policy behind this doctrine is that:

The public should . . . be able to act on the assumption that upon the expiration of the patent it will be free to use not only the invention claimed in the patent but also modifications or variants which would have been obvious to those of ordinary skill in the art at the time the invention was made, taking into account the skill in the art and prior art other than the invention claimed in the issued patent. In re Zickendraht, 319 F.2d 225, 232, 138 USPQ 22, 27 (CCPA 1963) (Rich, J., concurring).

Double patenting results when the right to exclude granted by a first patent is unjustly extended by the grant of a later issued patent or patents. In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982).

***Claim Rejections - 35 USC § 112, 1<sup>st</sup> paragraph***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 10 is rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabled for *treating* Alzheimer's Disease (see specification, page 1) does not

Art Unit: 1626

enable one skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims, for the reasons describe below.

As stated in MPEP 2164.01(a), “there are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is “undue.”

The factors to be considered when determining whether a disclosure meets the enablement requirement of 35 USC 112, first paragraph, were described in In re Wands, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988) as:

1. the nature of the invention;
2. the breadth of the claims;
3. the state of the prior art;
4. the relative skill of those in the art;
5. the predictability or unpredictability of the art;
6. the amount of direction or guidance presented [by the inventor];
7. the presence or absence of working examples; and
8. the quantity of experimentation necessary [to make and/or use the invention].

The eight Wands factors are applied to Claim 10 of the present invention below:

*(1) The Nature of the Invention*

Claim 10 is directed to a method of treatment of a subject suffering from or prone to Alzheimer’s Disease.

*(2) The Breadth of the claims*

Claim 10 will be given its broadest reasonable interpretation. The applicable rule for interpreting the claims is that “each claim must be separately analyzed and given its broadest

Art Unit: 1626

reasonable interpretation in light of and consistent with the written description.” See MPEP 2163(II)(1), citing In re Morris, 127 F.3d 1048, 1053-1054; 44 USPQ2d 1023, 1027 (Fed. Cir. 1997). In view of this rule, Claim 10 will be interpreted to mean the treatment and prevention of Alzheimer’s Disease.

*(3) The state of the prior art*

It was known in the art at the time of this application that the instantly claimed compounds can treat Alzheimer’s disease (See Specification page 1, Claim 16 of U.S. Patent Num. 7,041,689 and Claim 10 of U.S. Patent Num. 7,282,513).

*(4) The relative skill of those in the art*

The level of skill in the art (pharmaceutical chemists, physicians) would be high.

*(5) The predictability or unpredictability of the art*

It is noted that the pharmaceutical art generally is unpredictable, requiring each embodiment to be individually assessed for physiological activity. In cases involving unpredictable factors, such as most chemical reactions and physiological activity, the scope of enablement varies inversely with the degree of unpredictability in the factors involved. In re Fisher, 427 F.2d 833, 839. Therefore, the more unpredictable an area, the more specific enablement is needed in order to satisfy the statute. Added to the unpredictability of the art itself is the question whether a compound known to treat patients with Alzheimer’s Disease can also prevent it. There is no absolute predictability, even in view of the high level of skill in the art.

*(6) The amount of direction or guidance presented (by the inventor)*

The specification in the present invention discloses that the instantly claimed compounds can treat Alzheimer’s Disease, but Applicant’s specification does not provide support for preventing the diseases.

*(7) The presence or absence of working examples*

The instant specification only supports the general role of the instantly claimed compounds in treating Alzheimer's Disease, but not preventing it.

*(8) The quantity of experimentation necessary (to make and/or use the invention)*

Given the absence of direction or guidance (or working examples) in the specification for the role of the instantly claimed compounds in preventing Alzheimer's Disease, it would cause a skilled artisan an undue amount of experimentation to practice this invention to determine which patients with which diseases would benefit from which of the many claimed compounds within the scope of the invention with a reasonable expectation of success.

Applicant can overcome this rejection by deleting the term "or prone to" in claim 10.

***Objections***

Claim 11 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

***Telephone Inquiry***


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susannah Chung whose telephone number is (571) 272-6098. The examiner can normally be reached on M-F, 8am-5pm.

Art Unit: 1626

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on (571) 272-0699. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SLC



REBECCA ANDERSON  
PRIMARY EXAMINER

*for* Joseph K. McKane  
Supervisory Patent Examiner  
Art Unit 1626, Group 1620  
Technology Center 1600

Date: 17 October 2007